Detection Of Interleukin-33in Serum And Carcinoma Tissues In The Patients With Hepatocellular Carcinoma And Its Clinical Implication

Background and AimBankground:IL-33, ligand of ST2, is a new member of the IL-1family, it is also knownas IL-1F11.It is discovered in2005by Schmitz et.al. IL-33has a dual role, it can regulate theTH2immune response as a soluble cellular cytokine, stimulate mast cells to producepro-inflammatory factors, inhibit the transcription as a nuclear factor. The current studyfocused on the regulation of TH2immune response. Although low IL-33expression can bedetected in the liver with immunohistochemistry, but at present there are no relevantresearches on IL-33expression in liver tissue or blood in liver cancer. Aim: To observe theexpression and significance of intercellular(IL-33)in hepatocellular carcinoma.The liver cancer specimens were collected from60patientswho underwent liverresection for their first time in the Hepatobiliary Surgery Department, the First ClinicalHospital of Jilin University during the period from January,2010to October,2011, anddiagnosed with hepatocellular carcinoma after postoperative histologically pathologicalexaminations. This included43male and17female patients, aged from23to71years old,with an average of47years old.10healthy hospital staff volunteers, including8males and2females, aged from25to68years old, with an average of37.5years old.Tissue groups: HCCgroup (60cases), tumor surrounding liver group (60cases), non-neoplastic liver group (10cases)。 Serum groups: preoperative group(30cases),postoperative group (30cases),metastasis (15cases), without metastasis(15cases), non-neoplastic group (10cases)Experimental Materials and MethodsMethods：Immunohistochemical staining and image analysis were performed todetect the expression of IL-33in tissues of30cases of hepatocellular carcinoma,30casesof tumor surrounding liver and10cases of non-neoplastic liver. Expression of serumIFN-α,IFN-γ and IL-33in30patients with HCC and10cases of non-neoplastic subjectswere detected by using the techniques of ELISA. In addition,the results of studding on IL-33from HCC patients were analyzed with the relationship between lymph node metastasis.RESULT:Immunohistochemical：IL-33was localized in cell plasm, mesenchymal. can show weak positive.hepatocellular carcinoma group: IL-33was localized in cell plasm, positiverate was85%. tumor surrounding liver group:cell mesenchymal can show weak positive.positive rate was35%. normol liver group: a tiny minority liver cell expression of IL-33positive particles. positive rate was9%.ELISASerum IFN-α,Preoperative and postoperative group were all significantly higher thannormal group (P <0.01), more than10times. It’s a statistically significant difference. Itshowed no Significant difference between Preoperative and postoperative group. There wasno statistically significant. Serum IFN-γ, Preoperative and postoperative group were allsignificantly higher than normal group (P <0.01), more than5times. It’s a statisticallysignificant difference. It showed no Significant difference between Preoperative andpostoperative group. There was no statistically significant. SerumIL-33,Preoperative and postoperative group were all significantly higher than normalgroup (P <0.01), more than3times. It’s a statistically significant difference. Metastasisgroup is higher than non-metastasis group. There was statistically significant.Conclusion:The results suggest that, both highly expressed serum IL-33and high levelsof IL-33in HCC tissues, to a certain extent, reflect the degree of development of HCC andmetastasis. It is detected that IL-33and IFN-α, IFN-γ levels in serum were proportional tocorrelation with the pathological score, indicating that IL-33is activated in early liver cancer,and play a similar pro-inflammatory effect with IFN-α, IFN-γ, so IL-33may be used as anew diagnostic HCC indicators...